Answers are grounded in this paper and cite their sources.
Prospective cohort study finds that serum tryptase does not improve prognostic accuracy in COVID-19, indicating limited clinical utility.
In this prospective cohort, serum tryptase measured at admission was not associated with COVID-19 severity or mortality, suggesting limited utility as a prognostic biomarker. Established markers, particularly PCT and LDH, outperformed tryptase in predicting adverse clinical outcomes. The negative findings are clinically relevant as they demonstrate that tryptase does not contribute to prognostic risk stratification in COVID-19, and its measurement does not provide added value beyond standard inflammatory biomarkers.
No takes yet. Share an insight, caveat, or question.
Majeranowski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: